Translate the text from English to Welsh.



 
Lung cancer is the fourth most common cancer in Wales and the leading cause of cancer deaths. By increasing the use of non\-invasive liquid biopsy (blood sample) at an earlier stage of the cancer pathway, targeted treatments can be decided and administered quicker, improving patient outcomes and survival rates.  

  

Made possible through the All\-Wales Medical Genomics Service (AWMGS), Illumina technology, Life Sciences Hub Wales, and investment from multiple partner organisations, the new use of the blood test can detect multiple cancer markers without needing an invasive tissue biopsy.  

  

This new study will evaluate the benefits of liquid biopsy in people with suspected lung cancer. It will look at how its use earlier in the diagnostic process can improve and speed up diagnosis, reduce the time between diagnosis and treatment, and eventually inform how this technology can be rolled out to people with other types of suspected cancer.  

  

Liquid biopsy as a tool in genomic medicine is expected to become a pivotal part of healthcare and provide a better understanding of illnesses, improve patient outcomes and transform lives. In the future it has the potential to provide a simple, accessible and reliable means of investigating suspected cancer and less invasive monitoring for cancer recurrence.  

  

Testing the use of emerging technologies such as liquid biopsies is one example of how the Welsh Government plans to transform diagnostic services in Wales, as set out in the Diagnostic Strategy for Wales, launched today \[25th April]. This strategy will deliver services to reduce waiting times for diagnostic tests, improve patient outcomes, and support the diagnostic workforce across our NHS in Wales.  

  

The Minister for Health and Social Services, Eluned Morgan said:



> Wales has been leading the way in how we integrate genomic testing into health services to revolutionise how we deliver healthcare. Liquid biopsies could deliver real benefits for patients in Wales and save lives by helping us detect and treat cancers earlier.  
> 
>   
> 
> This is a key example of how working in partnership across a variety of sectors can contribute to improved health outcomes. This is part of our wider work to recover and transform services through the Diagnostic Strategy for Wales.


Craig Maxwell, patient representative of the QuicDNA steering group said:



> Being diagnosed at 40 with incurable and inoperable EGFR lung cancer I have first\-hand experience with the cancer diagnostic pathway in Wales. Wales is so lucky to have amazing nurses and doctors who support us through this pathway, we all have a responsibility to make sure they have the best and most up\-to\-date technology available to them to support the diagnostic pathway. This clinical study is a major step forward in helping cancer patients, like myself.  
> 
>   
> 
> From the point of discovering my tumour, it took a stressful and hard 72 days to identify my cancer but this new technology will help support and deliver results quicker, allowing cancer patients to get treatment sooner and help them plan, with their families for the new life that exists in front of them. Let’s make sure all of Wales has access to these new innovative tests, and our amazing nurses and doctors have access to this technology to help them help us.


 







Translation:


 
Canser yr ysgyfaint yw’r pedwerydd mwyaf cyffredin yng Nghymru a’r canser sy’n achosi’r nifer mwyaf o farwolaethau. Drwy gynyddu’r defnydd o fiopsi hylif anfewnwthiol (sampl gwaed) yn gynharach yn y llwybr canser, gellir gwneud penderfyniadau cyflymach am driniaethau wedi’u targedu, a darparu’r triniaethau hynny’n gynt hefyd. Bydd hyn yn gwella canlyniadau cleifion a chyfraddau goroesi.  

  

Mae’r defnydd newydd o’r prawf gwaed yn bosibl diolch i Wasanaeth Genomeg Meddygol Cymru Gyfan, technoleg Illumina, Hwb Gwyddorau Bywyd Cymru, a buddsoddiad gan sawl sefydliad sy’n bartneriaid yn y fenter. Gall y defnydd newydd o’r prawf gwaed ganfod marcwyr canser lluosog heb fod angen biopsi meinwe mewnwthiol.  

  

Bydd yr astudiaeth newydd hon yn gwerthuso manteision biopsi hylif pan fo amheuaeth bod gan rywun ganser yr ysgyfaint. Bydd yn edrych ar sut y gall ei ddefnyddio’n gynharach yn y broses ddiagnostig wella a chyflymu diagnosis a lleihau’r amser rhwng diagnosis a thriniaeth. Bydd hefyd yn helpu i ddeall sut y gellir defnyddio’r dechnoleg hon pan fo amheuaeth bod gan rywun fathau eraill o ganser.  

  

Mae disgwyl i’r defnydd o fiopsi hylif ym maes meddygaeth genomig ddod yn rhan ganolog o ofal iechyd a rhoi dealltwriaeth well o salwch, gwella canlyniadau cleifion a thrawsnewid bywydau. Yn y dyfodol, mae ganddo’r potensial i ddarparu ffordd syml, hwylus a dibynadwy o archwilio canser a amheuir a ffordd lai mewnwthiol o fonitro ar gyfer canser yn dychwelyd.  

  

Mae profi’r defnydd o dechnolegau newydd megis biopsi hylif yn un enghraifft o’r ffordd y mae Llywodraeth Cymru yn bwriadu trawsnewid gwasanaethau diagnostig yng Nghymru, fel y nodir yn Strategaeth Ddiagnosteg Cymru sy’n cael ei lansio heddiw \[25 Ebrill]. Bydd y strategaeth hon yn darparu gwasanaethau i leihau amseroedd aros profion diagnostig, gwella canlyniadau cleifion, a chefnogi’r gweithlu diagnostig ar draws ein Gwasanaeth Iechyd yng Nghymru.  

  

Dywedodd y Gweinidog Iechyd a Gwasanaethau Cymdeithasol, Eluned Morgan:



> Mae Cymru wedi bod yn arwain y ffordd o ran sut rydyn ni’n integreiddio profion genomig mewn gwasanaethau iechyd i chwyldroi gofal iechyd. Fe allai biopsi hylif roi manteision gwirioneddol i gleifion yng Nghymru ac achub bywydau drwy’n helpu ni i ganfod a thrin canser yn gynharach.  
> 
>   
> 
> Dyma enghraifft allweddol o sut all gweithio mewn partneriaeth ar draws sawl sector gyfrannu at ganlyniadau iechyd gwell. Mae hyn yn rhan o’n gwaith ehangach i adfer a thrawsnewid gwasanaethau drwy Strategaeth Ddiagnosteg Cymru.


Dywedodd Craig Maxwell, cynrychiolydd cleifion y grŵp llywio QuicDNA:



> Cefais ddiagnosis o ganser yr ysgyfaint EGFR nad oedd modd ei wella na’i drin drwy lawdriniaeth pan o’n i’n 40 oed. Mae gen i felly brofiad uniongyrchol o’r llwybr diagnostig ar gyfer canser yng Nghymru. Mae Cymru mor ffodus o’i nyrsys a’i meddygon ardderchog sy’n ein cefnogi ar y llwybr hwn. Mae cyfrifoldeb arnon ni i gyd i wneud yn siŵr bod y dechnoleg orau a diweddaraf ar gael iddyn nhw i gynnal y llwybr diagnostig. Mae’r astudiaeth glinigol hon yn gam mawr ymlaen i helpu cleifion canser, fel fi.  
> 
>   
> 
> Ar ôl i fy nhiwmor gael ei ddarganfod, cymerodd hi 72 o ddiwrnodau anodd, llawn straen, i wybod pa fath o ganser oedd gen i. Bydd y dechnoleg newydd hon yn helpu i roi canlyniadau’n gyflymach, gan alluogi cleifion canser i gael triniaeth yn gynharach a’u helpu i gynllunio, gyda’u teuluoedd, at y bywyd newydd sydd o’u blaenau. Rhaid inni sicrhau bod y profion arloesol newydd hyn ar gael ym mhob rhan o Gymru, ac y gall ein nyrsys a’n meddygon ardderchog ddefnyddio’r dechnoleg hon i’w helpu nhw i’n helpu ni.